Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 20, 2026American Journal of Respiratory and Critical Care Medicine

A52-05 Use of Etomidate to Reduce Pressor Requirements in a Patient With Severe Ectopic Acth Syndrome Presenting With Shock

View Full Paper
Ask AI
Bookmark
Share

Authors

JOJ OuyangZUZ UmarFMF Mehdi

Discussion

Loading...

Member takes

Overview

Case report demonstrates etomidate's effectiveness in reducing pressor needs in a critically ill patient.

Key Points

  • The aim is to evaluate the impact of etomidate on cortisol levels and pressor requirements in a patient with ectopic ACTH syndrome.
  • Administered etomidate infusion to manage severe hypercortisolism in an ICU patient.
  • Monitored mean arterial pressure and adjusted norepinephrine and vasopressin doses accordingly.
  • Documented changes in cortisol levels and pressor requirements over five days.
  • Cortisol levels decreased from 128 mcg/dL to ∼30 mcg/dL after etomidate infusion.
  • Norepinephrine dose reduced from 30 mcg/min to 5 mcg/min during etomidate treatment.
  • Patient continued to require vasopressin, highlighting dependence on exogenous administration.

Cite This Study

Ouyang et al. (2026) studied this question.

synapsesocial.com/papers/6a0d50bdf03e14405aa9cbachttps://doi.org/10.1093/ajrccm/aamag162.3173
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 18281 Continuous Low-Dose Etomidate Infusion For The Management Of Severe Hypercortisolism In Metastatic Adrenocortical Carcinoma2024
  2. 27117 Cushings Conundrum: Taming The Hormone Hurricane2024
  3. 3Etomidate Monotherapy for Perioperative Control of Hypercortisolism in a Mitotane-Intolerant Patient With Adrenocortical Carcinoma: A Case Report2026
  4. 4Normalization of Potassium Despite 11-Deoxycorticosterone Rise During Etomidate Therapy in Adrenocortical Carcinoma2026
  5. 5212: ETOMIDATE, KETOCONAZOLE, AND MITOTANE FOR CUSHING DISEASE DUE TO ADRENOCORTICAL CARCINOMA2026